<DOC>
	<DOC>NCT01289249</DOC>
	<brief_summary>The object of the study is to investigate whether all included patients receive treatment that is effective against all bacteria that are defined as sensitive to meropenem with the current treatment regimen. Will the investigators findings motivate routine monitoring of plasma concentrations in children receiving meropenem? Up to 50 patients will be included in the study, and all participants are children.</brief_summary>
	<brief_title>Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Children aged from 3 months to 18 years that receive treatment with meropenem. Inclusion is independent of how long the patient has been receiving treatment. Children receiving other treatment (except hemodialysis)/other medications can be included. Children less than three months of age. Patients receiving hemodialysis. Lack of consent.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>meropenem</keyword>
	<keyword>child</keyword>
	<keyword>bacterial infection</keyword>
	<keyword>treatment evaluation</keyword>
</DOC>